Abstract
Background and hypothesis: Although medical therapy may normalize echocardiographic left ventricular (LV) systolic function in selected patients with cardiomyopathy, other patients experience no change or a further deterioration in heart failure remodeling. Our aim was to determine what clinical or echocardiographic parameters predict a beneficial therapeutic response.
Methods: We prospectively followed biannual clinical and echocardiographic assessments in 215 patients. Forty‐six of these patients (“Nonresponders”) experienced no change or a decline in LV ejection fraction at 6 months. Of the 148 patients who improved LV function, 21 (“Responders”) normalized LV systolic function at 6 months. Only Responders (n = 21) and Nonresponders (n = 46) were compared.
Results: On average, these 67 patients were 54 ± 12 years old with 4.5 ± 3.3 years of heart failure. At 6 months, following uptitration of angiotensin‐converting enzyme inhibitors and nitrates, Responder LV ejection fraction rose from 22 ± 6 to 50 ± 5% with improvement in New York Heart Association classification (2.6 ± 0.8 to 1.5 ± 0.8, p = 0.001). These patients had significantly more favorable clinical and echocardiographic outcomes versus Nonresponders despite comparable medical therapy. All baseline demographic, clinical, and echocardiographic variables were equivalent, except for initial LV end‐diastolic diameter which differentiated Nonresponders (7.1 ± 0.7 cm) from Responders (6.1 ± 0.8 cm), p = 0.007.
Conclusion: Thus, although heart failure therapy improves LV systolic function in a majority of patients, with normalization in up to 10% of patients, significant LV enlargement may render remodeling unresponsive to pharmacologic intervention, with a potential future need for alternative mechanical or surgical intervention.
Keywords: heart failure remodeling, angiotensin‐converting enzyme inhibitors, nitrates, left ventricular size
Full Text
The Full Text of this article is available as a PDF (446.4 KB).
Reference
- 1. Cohn JN: Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91: 2504–2507 [DOI] [PubMed] [Google Scholar]
- 2. Sabbah HN, Kono T, Stein PD, Mancini J, Goldstein S: Left ventricular shape changes during the course of evolving heart failure. Am J Physiol 263 (Heart Circ Physiol 32 )1992; H266–H270 [DOI] [PubMed]
- 3. The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Surgical Study. N Engl J Med 1987; 316: 1429–1435 [DOI] [PubMed] [Google Scholar]
- 4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman B, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes V, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine‐isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325 (5): 303–310 [DOI] [PubMed] [Google Scholar]
- 5. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 293–302 [DOI] [PubMed] [Google Scholar]
- 6. The SOLVD Investigators : Effect of enalapril on mortality and the development of heart failure in symptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691 [DOI] [PubMed] [Google Scholar]
- 7. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, for the SOLVD Investigators : Effects of the angiotensin‐converting enzyme inhibitor enalapril on the long‐term progression of ventricular dysfunction in patients with heart failure. Circulation 1992; 86: 431–438 [DOI] [PubMed] [Google Scholar]
- 8. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelto B, for the SOLVD Investigators : Effects of long‐term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: Results of the SOLVD echocardiography substudy. Circulation 1995; 91: 2573–2581 [DOI] [PubMed] [Google Scholar]
- 9. Waagstein F, Bristow M, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy Trial Study Group : Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–1446 [DOI] [PubMed] [Google Scholar]
- 10. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double‐blind randomized study. J Am Coll Cardiol 1995; 25: 1225–1231 [DOI] [PubMed] [Google Scholar]
- 11. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, Grayburn PA: Effect of beta‐adrenergic blockage on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990; 82: 473–483 [DOI] [PubMed] [Google Scholar]
- 12. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta‐adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154–1161 [DOI] [PubMed] [Google Scholar]
- 13. Levine TB, Levine AB, Keteyian SJ, Narins B, Lesch M: Reverse remodeling in heart failure with intensification of vasodilator therapy. Clin Cardiol 1997; 20: 697–702 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Levine TB, Levine AB, Keteyian SJ, Kline DA: Response of ischemic versus nonischemic cardiomyopathy with intensification of vasodilator therapy. Cong Heart Failure 1998;Mar/Apr: 15–22
- 15. Levine TB, Levine AB, Kathawala M, Narins B, Kaminski P: Paradoxical hypertension after reversal of heart failure in patients treated with intensive vasodilator therapy. Am J Hypertens 1998; 11 (9): 1041–1047 [DOI] [PubMed] [Google Scholar]
- 16. Levine AB, Muller C, Levine TB: Effects of high‐dose lisinoprilisosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. Am J Cardiol 1998; 82: 1299–1301 [DOI] [PubMed] [Google Scholar]